ProCE Banner Activity

CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

Podcast Episodes

Listen to Julio C. Chavez, MD, MS, a medical oncologist based in an academic center, and Alan Skarbnik, MD, a medical oncologist based in the community, discuss the emerging role of CELMoDs in non-Hodgkin lymphoma care, including available data and ongoing clinical trials with these agents.

Released: July 11, 2024

Expiration: July 10, 2025

Share

Faculty

Julio C Chavez

Julio C Chavez, MD, MS

Associate Member
ICE-T Clinical Research Medical Director Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, Florida

Alan Skarbnik

Alan Skarbnik, MD

Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Disclosure

Primary Author

Julio C Chavez, MD, MS

Associate Member
ICE-T Clinical Research Medical Director Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, Florida

Julio C. Chavez, MD, MS: researcher: Genmab, Kite/Gilead, Merck; consultant/advisor/speaker: Allogene, AstraZeneca, Bristol Myers Squibb, Cellectar, Genmab, Kite/Gilead, Novartis; independent contractor: BeiGene, Lilly.

Alan Skarbnik, MD

Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina

Alan Skarbnik, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Genentech, Janssen, Jazz, Kite, Lilly, Pharmacyclics, SeaGen.